36 results about "Hydrocortisone" patented technology

The invention provides a 3-hydroxypyrone derivative as well as a preparation method and application thereof, the compound can effectively inhibit release of proinflammatory cytokines in lipopolysaccharide-induced microglial cells, inhibit release of NO by the lipopolysaccharide-induced microglial cells, inhibit apoptosis of polysaccharide-induced microglial cells, and inhibit apoptosis of lipopolysaccharide-induced microglial cells. The compound has excellent anti-neuroinflammation activity and neuroprotective effect, the activity of the compound is superior to that of positive controls such as curcumin and hydrocortisone, and the compound can be used for preventing and / or treating neuroinflammation and neurodegenerative diseases.

The invention discloses application of phosphatidylserine-hydrocortisone microvesicles in preparation of a medicine for treating microvascular regeneration after cerebral apoplexy, and relates to the technical field of biomedicine. According to the microbubble, the blood brain barrier can be accurately opened through the ultrasonic vacuolation technology, the medicine can be delivered in a targeted mode, nerve protection and function improvement are accurately evaluated through ultrasonic super-resolution micro blood flow imaging, and microvessel regeneration is accurately regulated and controlled based on H3K18 lactic acid modification.

The application relates to the technical field of animal model construction, in particular to a construction method and application of a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model. The construction method comprises the following steps: a model group animal is subjected to modeling by adopting the method of senna leaf water decoction gavage and hydrocortisone and cyclophosphamide injection, and a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model is obtained. In the application, the three of senna leaf, hydrocortisone and cyclophosphamide are used in synergy to administer the animal model, and the complex syndrome of the clinical spleen-kidney yang deficiency type DOR is accurately reproduced, and modern scientific basis is provided for the theories of traditional Chinese medicine such as the same treatment for different diseases.

The invention relates to a culture method and a culture medium for reducing the number of differential transcripts of epithelial organoid and in-vivo tissues, and solves the technical problems of low growth rate and low formation rate of the organoid in the prior art. The basic components of the culture medium comprise a DMEM / F12 basal culture medium, a penicillin-streptomycin solution, a Glutamax additive, a recombinant spinal protein, a recombinant head protein, Y-27632, an epidermal growth factor, an N-2-hydroxyethyl piperazine-N-2-ethanesulfonic acid buffer solution, nicotinamide, A83-01 and CHIR99021, and the additional components of the culture medium comprise a Wnt-3A additive, an ITS-X additive and hydrocortisone. The invention also provides a culture method of the epithelial organoid. The method can be used for culturing epithelial organs.

The present invention belongs to the technical field of biomedicine, and specifically relates to a nociceptor skin organoid chip and its culture medium, construction method and application. A culture medium for a nociceptor skin organoid chip, the culture medium is composed of fetal bovine serum and the following components added to the fetal bovine serum: epidermal growth factor, bovine pituitary extract, Normocin, B27, nerve growth factor, insulin, hydrocortisone, human brain-derived neurotrophic factor and capsaicin. Using this culture medium to co-culture a skin chip with nociceptors to obtain a nociceptor skin organoid chip, which can be used for the verification of pain perception effects.

Orodispersible film (ODF) is an innovative drug formulation that allows for adjustable dosing and improved patient compliance. It is administered into the mouth where it dissolves, making it suitable for children. The present invention provides an optimized ODF gel formulation and an optimal ODF containing therapeutic doses of hydrocortisone-type corticosteroids (HTC). This ODF is thin, flexible and transparent, and suitable for production in hospital pharmacy using standard equipment. The ODF of the invention allows accurate hydrocortisone levels to be released systemically in patients in need thereof, and its good physico-chemical stability is herein demonstrated for several months. This opens up new opportunities for use in pediatric patients, notably for children suffering from congenital adrenal hyperplasia.

This invention relates to a method for constructing and evaluating an animal model of Alzheimer's disease characterized by deficiency and blood stasis. Based on APP / PS1 mice, the model was induced by sleep deprivation, hydrocortisone, and carrageenan to induce qi deficiency, kidney deficiency, and blood stasis, respectively, for a total modeling period of 28 days, resulting in an animal model of Alzheimer's disease with deficiency and blood stasis. This model was constructed using a multi-factor combined approach, and its symptom manifestations are consistent with clinical observations. It is simple, effective, and easy to operate, providing a reliable experimental vehicle for the development of innovative drugs and the study of mechanisms of action in Alzheimer's disease with deficiency and blood stasis.

The present application relates to a culture method and culture medium for reducing the number of epithelial organoids and in vivo tissue differential transcripts, which solves the technical problems of low growth rate and low formation rate of organoids in the prior art. The epithelial organoid culture medium contains basic components and additional components. The basic components contain DMEM / F12 basic medium, penicillin-streptomycin solution, Glutamax additive, recombinant vertebral protein, recombinant cephalopod protein, Y-27632, epidermal growth factor, N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer solution, nicotinamide, A83-01 and CHIR99021. The additional components contain Wnt-3A, ITS-X additive and hydrocortisone. The present application simultaneously provides a culture method for epithelial organoids. The present application can be used for the culture of epithelial organoids.

Provided herein are oral liquid formulations of hydrocortisone. Also provided herein are methods of making and using hydrocortisone oral liquid compositions for the treatment of certain diseases including endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, and others.

The present invention discloses a carbonyl reductase mutant and its application in synthesizing 11β-hydroxysteroid compounds. Carbonyl reductase derived from Homo sapiens is modified by semi-rational design methods to provide a carbonyl reductase mutant. The mutant can efficiently catalyze the synthesis of 11β-hydroxysteroid compounds prednisolone, hydrocortisone and methylprednisolone using prednisone, cortisone and methylprednisolone as substrates.

This disclosure provides fast acting itch relief and cooling sprays containing hydrocortisone, a cooling agent, such as sensate molecule (e.g. menthyl lactate), and a soothing agent (such as e.g., Aloe vera). The sprays of the disclosure can be used to relieve itching associated with minor skin irritations, inflammation, and rashes due to eczema, psoriasis, poison ivy, oak, sumac, insect bites, detergents, jewelry, cosmetics, soaps, seborrheic dermatitis. The disclosure also provides for methods of treating skin with cooling sprays as well as containers containing the spray.

The invention discloses a hydrocortisone compound ointment preparation for treating haemorrhoids, and belongs to the technical field of medicines. The technical problem to be solved is to provide a hydrocortisone compound ointment preparation which has a good hemorrhoid treatment effect and is stable. The hydrocortisone compound ointment preparation comprises the following components in percentage by weight: 0.15%-1% of corticoid, 0.025%-0.1% of a vasoconstrictor, 2%-4% of a local anesthetic, 0.1%-1.5% of L-menthol, 0.02%-0.5% of chlorhexidine acetate and 0.05%-1% of allantoin. The hydrocortisone compound ointment preparation disclosed by the invention has the medicinal effects of relieving pain and discomfort of patients suffering from haemorrhoids, promoting healing and repairing of haemorrhoids tissues, preventing infection and relieving inflammatory response, and has obvious effects of stopping bleeding and relieving swelling and pain in haemorrhoids treatment.

The invention relates to the technical field of biology, in particular to a dissociation agent and a kit for progesterone determination. According to the invention, the sample dissociation agent for progesterone detection is obtained through optimized screening, and the sample dissociation agent comprises hydrocortisone, prednisolone and mono (2-ethylhexyl) phthalate (MEHP); when the dissociation agent components act independently or in a combined mode, the sensitivity to sample detection is high, the detection linear range is good, the dissociation agent is well related to a comparison reagent, the dissociation effect is improved remarkably on the whole, progesterone can be better released from corticosteroid binding protein, albumin and sex hormone binding globulin, and the progesterone dissociation agent is suitable for being used for detecting progesterone. The combination of progesterone and a captured antibody is facilitated, and the sensitivity and the accuracy can be effectively improved. Moreover, the reagent can be directly added into reagent components, so that the dissociation process and the immune reaction are carried out at the same time, the immune reaction is simple and efficient, and the reaction efficiency is improved.

The invention discloses a hydrocortisone butyrate cream and a preparation method thereof. Each gram of the hydrocortisone butyrate cream comprises the following components: 1 mg of hydrocortisone butyrate, 100-120 mg of an oil phase solid, 100-150 mg of white vaseline, 40-60 mg of light liquid paraffin, 30-40 mg of an emulsifier, 5-20 mg of salicylic acid, 10-40 mg of lecithin, 50-80 mg of a humectant, 1-2 mg of anhydrous sodium citrate, and the balance of water. On the basis of the existing prescription, the salicylic acid and the lecithin are added into the formula, and the dosages of the salicylic acid, the lecithin and other auxiliary materials are controlled, so that the hydrocortisone butyrate cream which is small in generation amount of degraded impurities and relatively good in stability is obtained.

The invention discloses a pharmaceutical composition for chronic scytitis, and belongs to the technical field of pharmaceutical compositions. The pharmaceutical composition for scytitis comprises an ethanol solution of a tripterygium wilfordii extract with the concentration of 15 mg / mL and a hydrocortisone solution with the mass percentage content of 1%. The combination of the tripterygium wilfordii extract and the hydrocortisone in the pharmaceutical composition for skin inflammation has a good synergistic anti-inflammatory effect, and side effects of the hydrocortisone are reduced.

The present disclosure relates generally to the treatment of adrenal dysfunction (such as congenital adrenal hyperplasia) with a combination of 2‑thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-2-propyn-1-yl (crinecerfont) and certain pharmaceutical compositions of hydrocortisone (such as a delayed release oral pharmaceutical composition of hydrocortisone).

The present application relates to the technical field of gout treatment, and more specifically, it relates to a serrata huperzine derivative, a preparation method thereof, and its application in anti-gout drugs. In the first aspect, the present application discloses a serrata huperzine derivative compound having the general formula (I) below; in the second aspect, the present application discloses a preparation method of the above-mentioned serrata huperzine derivative; in the third aspect, the serrata huperzine derivative of the present application can be used in gouty arthritis, and such serrata huperzine derivatives represented by 3k and 3q significantly inhibit the release of IL-1β induced by sodium urate at a concentration of 30 μM. Compared with the clinical anti-inflammatory drugs hydrocortisone, indomethacin, and colchicine, the serrata huperzine derivatives of the present application have a good balance between high inhibitory activity and low cytotoxicity, and have good application prospects. #imgabs0#

This invention belongs to the field of regenerative medicine, specifically relating to a lacrimal gland organoid culture medium and a method for in vitro culture of lacrimal gland organoids. In one aspect, a lacrimal gland stem cell proliferation culture medium is provided, comprising: lacrimal gland stem cell basal culture medium, EGF, Wnt3a, FGF7, FGF10, RSP1, and Noggin; the lacrimal gland stem cell basal culture medium comprises: DMEM medium, F12 medium, L-glutamine, fetal bovine serum, hydrocortisone, cholera toxin, B27, penicillin, streptomycin, amphotericin B, and fasudil. In another aspect, a lacrimal gland stem cell differentiation culture medium is provided, comprising: lacrimal gland stem cell basal culture medium, EGF, Wnt3a, FGF7, FGF10, RSP1, Noggin, and BMP7. The lacrimal gland organoids constructed by this invention are larger in volume than those of existing technologies, possessing numerous branched ducts and vesicular acinar structures, extending radially and multidirectionally in a three-dimensional manner, forming a complex and regular three-dimensional tubular acinar network, and possessing secretory function.

The invention provides a method for producing porcine rotavirus based on suspension culture of a PK15 cell reactor, and belongs to the technical field of large-scale preparation of veterinary virus biological products. A Trans VA-06 special culture medium containing functional components such as hydrocortisone, IGF-1 and cholesterol is adopted, a PK15 cell high-density suspension system is constructed in a reactor, harvesting is conducted within 20-36 h when CPE is larger than or equal to 80% by accurately regulating and controlling the initial inoculation density, the culture volume, the stirring rotating speed and the ventilation / oxygen flux and cooperating with a virus inoculation strategy for fixing MOI, and it is shown through multiple batches of results that the PK15 cell high-density suspension system can be obtained. The titer of the obtained virus is stably 9.0 to 10.0 log10 TCID50 / mL, and the repeatability among batches is excellent; according to the method, the large-scale production efficiency and the product quality stability are improved, and the method is suitable for industrial production of the porcine rotavirus vaccine.

The invention discloses a mouse oral squamous cell carcinoma organoid and spleen T cell immune co-culture system and a culture medium, a culture method and application thereof.The culture medium of the co-culture system comprises an oral squamous cell carcinoma organoid culture medium and a T cell culture medium, and the oral squamous cell carcinoma organoid culture medium comprises Advanced DMEM / F12. And the following components based on Advanced DMEM / F12: 5% of fetal calf serum, 1% of a penicillin-streptomycin solution, 1% of B27, 5 ng / ml of EGF, 5 [mu] g / ml of insulin, 40 ng / ml of hydrocortisone, 25 mmol / L of N-acetyl-L-cysteine and 10 mmol / L of nicotinamide. The organoid culture medium provided by the invention is more beneficial to formation of mouse oral squamous cell carcinoma organoid balls and maintenance of stable cell morphology during in-vitro culture, while an existing commercially available culture medium is easy to cause excessive adherent growth of cells. The culture medium of the co-culture system provided by the invention provides a reference path and an experimental model for construction of a co-culture system of clinical patient-derived tumor organs and T cells.

The invention belongs to the technical field of biology, and particularly relates to a culture medium capable of differentiating and inducing amniotic fluid cells into myoblasts, a method and application. The culture medium contains 5% v / v serum, 0.1 [mu] M of dexamethasone, 50 [mu] M of hydrocortisone, 1 [mu] M of MCHIR99021 and 5-10 ng / mL of IGF-1, and a solvent is a low-sugar DMEM (Dulbecco Modified Eagle Medium). According to the invention, amniotic fluid cells are separated from amniotic fluid, and myoblasts can be obtained by using the culture medium to culture, differentiate and induce. According to the invention, efficient muscle differentiation and RYR1 gene overexpression of amniotic fluid cells are realized for the first time, and the gene has high fidelity on splicing variation after induced differentiation, so that a safe, rapid and low-cost solution is provided for prenatal clear gene diagnosis.

Provided is a compound hydrocortisone and neomycin sulfate granule, including the following components in parts by mass: 140 parts of acetaminophen, 1 part of chlorpheniramine maleate, 1.2 parts of methylephedrine hydrochloride, 2 to 2.5 parts of an inclusion stabilizer, 3.0 parts of artificial calculus bovis, and 0.5 to 1 parts of a caramel. In a method for preparing the compound hydrocortisone and neomycin sulfate granule, natural Chinese medicinal herbs are subjected to extraction to obtain natural stabilizers for stabilizing low-concentration acetaminophen and chlorpheniramine maleate, and the natural stabilizers are encapsulated with hydroxypropyl-β-cyclodextrin with a specific degree of substitution (DS).

The invention relates to a prednisolone crude product mother liquor recovery treatment method. The method comprises the following steps: S1, obtaining a prednisolone crude product mother liquor; s2, standing and layering the crude product mother liquor, and separating to obtain supernatant and subnatant after layering; s3, performing vacuum concentration on the supernatant, then mixing the supernatant with the subnatant, performing acidizing treatment, and performing solid-liquid separation after acidizing treatment to obtain an acidized solid; and S4, placing the acidified solid in a dichloromethane-methanol mixed solution, then adding water, carrying out crystallization treatment, and filtering the solid obtained by crystallization to obtain a recovered solid. Hydrocortisone and prednisolone in the prednisolone crude product mother liquor are recovered and then can be recovered for prednisolone production, so that the product yield of prednisolone can be improved, the raw material cost can be reduced, and meanwhile, the pollution and waste treatment cost can also be reduced.

The present invention provides methods and pharmaceutical compositions for treating subjects with hepatic fibrosis and / or cirrhosis. [Solution] A method is provided for treating a subject with hepatic fibrosis, comprising administering a pharmaceutical composition containing hydronidone or a salt thereof to the subject. Liver stiffness measurements and / or ishax scores may be used to identify a subject for treatment of hepatic fibrosis and / or cirrhosis.

Cell culture media are disclosed. The cell culture media include species-specific cell culture media containing species bFGF, species PDGF-BB, and species EGF, and species serum. Further, a canine cell culture medium is disclosed containing canine bFGF, canine PDGF-BB, and canine EGF, and canine serum. A composition is described, including a medium containing basal medium, sodium bicarbonate, HEPES, L-glutamine, L-alanine, insulin, hydrocortisone, progesterone, Asc-2-p, holo-transferrin, species bFGF, species PDGF-BB, and species EGF, serum matching the species cells, and species MSC cells. A method for producing exosomes is described, the method comprising expanding mesenchymal stem cells and / or islet cells in culture, culturing the cells, and collecting exosomes released by the mesenchymal cells and / or adipose stem cells in the culture.

Formulations comprising hydrocortisone are disclosed in a suppository for methods of treating ulcerative colitis and other gastrointestinal diseases and disorders. Administering a single hydrocortisone suppository once a day achieves remission or reduction of a symptom, optionally followed by a period of time in which the dosage is reduced.

Use of hydronidone in the preparation of a medicament for preventing and / or treating chronic kidney disease.

The present invention discloses a tetramer of Met-Pro-Ser, namely [Met-Pro-Ser]<subgt;4< / subgt;, discloses its preparation method and the therapeutic effect on testes damaged by hydrocortisone. Experiments prove that the [Met-Pro-Ser]<subgt;4< / subgt; of the present invention can not only effectively treat testes damaged by hydrocortisone, but also the curative effect of treating testes damaged by hydrocortisone is significantly stronger than that of Met-Pro-Ser in treating testes damaged by hydrocortisone. Therefore, it is proposed that the present invention provides an effective technical means for treating testes damaged by hydrocortisone.

This invention discloses a composite culture medium with defined components for co-culturing multiple cell types, along with its usage and applications. The culture medium can be used for long-term, stable triadic co-culture of patient-derived glioma stem cells, patient-derived T cells, and THP-1 macrophages (or patient-derived macrophages). The culture medium includes basal medium and EGF, bFGF, IL-2, M-CSF, ITS, and hydrocortisone. Furthermore, this invention provides optimized cell ratios and culture methods, achieving proliferation results that simultaneously maintain GSC stemness, primary T cell activity, and THP-1-derived macrophage activity for up to 14 days in the same system.

The disclosure provides a hemorrhoid splinting device intended for insertion into the anorectal cavity of a human. The device includes an elongated, fusiform body with a middle portion of larger diameter that tapers to smaller-diameter distal and proximal ends, where the distal end is rounded and the proximal end includes a handle. The device may feature surface recesses for administering medication, and / or an internal cavity for substances that retain coolant or heat. Another embodiment of the device includes an outer perforated skin layer for controlled release of therapeutic agents. Medications, such as hydrocortisone or witch hazel, may be applied to the recesses or positioned between the body and skin layer. Methods of treating hemorrhoids include inserting the device and maintaining the device inserted for a period of time.